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Controlled Substance Take-Back
The Iowa Governor’s Office of Drug Control Policy (ODCP) has 
created a new map showing all of the permanent controlled substance 
(CS) drop-off locations at law enforcement offices throughout the 
state of Iowa. This map can be found by visiting the ODCP website 
at www.iowa.gov/odcp/drug_information/takebacks.html and click-
ing on the “Take Back sites” link located in the subsection titled 
“Permanent Local ‘Take Back’ Sites for ALL Medicines in Iowa.”
Additionally, any manufacturer, distributor, reverse distributor, 
narcotic treatment program, hospital/clinic with an on-site phar-
macy, and retail pharmacy with the authority to handle Schedule II 
CS may register with Drug Enforcement Administration (DEA) as 
an “authorized collector.” Registration with DEA is free and can 
be done online at www.deadiversion.usdoj.gov. Once the registra-
tion is authorized by DEA, the entity may begin collecting CS in 
accordance with DEA rules. Currently, no additional registration 
or notification is required through the Iowa Board of Pharmacy.
Rules pertaining to the operation and record-keeping requirements 
for entities registered with DEA as CS take-back sites may be found 
at www.deadiversion.usdoj.gov/fed_regs/rules/2014/2014-20926.pdf.
PMP Omissions From Pharmacy Software
By Mark Mather, RPh, Board Compliance Officer
The Board office has recently received several phone calls from 
pharmacies wondering why omissions were found in their weekly 
Iowa Prescription Monitoring Program (PMP) submissions. In most 
cases, the pharmacy involved employed its software vendor to submit 
the data on its behalf. In most cases, the omissions were caused by 
an incomplete order entry or patient data entry; eg, required data 
fields, such as the patient’s telephone number, zip code, or state of 
residence, had been left blank. Filling in all required data fields is 
paramount for complete PMP data submission.
A very useful tool called the PMP Data Reporting Manual can 
be found on the Board’s website at https://pharmacy.iowa.gov/ 
document/pmp-data-collection-manual. On pages 11-12, there is 
a chart listing all the required data elements; pages 7-8 touch on 
rejections, errors, and, most importantly, corrections.
What else can be done to help pharmacies that use a software 
vendor for submitting PMP data? First and foremost, the pharmacy 
needs to have a discussion with its software vendor on what hap-
pens with records that are rejected for errors. Ask the vendor how 
often error records are sent back to the pharmacy and by what 
method – email, fax, or letter? It is important that software vendors 
timely notify pharmacies of records that were rejected due to errors. 
Some software vendors may have more than one type of reporting 
process. The pharmacy needs to understand how to correct error 
notifications. If pharmacies do not follow-up on error notifications, 
then the software vendors cannot do anything more to help correct 
the omissions. Please refer to the PMP Data Reporting Manual on 
the Board website for more information.
Prescriptions Generated From a 
Telemedicine Encounter: Are They Valid 
Prescriptions?
The Iowa Board of Medicine recently adopted rules governing 
the practice of telemedicine. Traditionally, the patient-prescriber 
relationship began when the patient was seen, in person, by the 
prescriber. However, technological advances have permitted 
patient-prescriber interactions by other means than in-person vis-
its. As such, the Board of Medicine has identified ways in which 
a patient-prescriber relationship may be established without an 
in-person examination.
The ways the Board of Medicine have identified by which a 
patient-prescriber relationship may be established are as follows:
 ♦ Through an in-person medical interview and physical 
examination where the standard of care would require an 
in-person encounter.
 ♦ Through consultation with another licensee (or other health 
care provider) who has an established relationship with the 
patient and who agrees to participate in, or supervise, the 
patient’s care.
 ♦ Through telemedicine, if the standard of care does not require 
an in-person encounter, and in accordance with evidence-
based standards of practice and telemedicine practice guide-
lines that address the clinical and technological aspects of 
telemedicine.
Other requirements that the pharmacist should consider prior to 
filling a prescription generated by a telemedicine encounter include:
 ♦ Verifying that the physician is licensed to practice medicine 
in the state of Iowa.
 ♦ Identifying whether or not the encounter was based on an 
Internet questionnaire that was a static set of questions 
provided to the patient to which the patient responded with 
a static set of answers, or that the encounter was solely 
telephonic in nature (devoid of the establishment of a 
patient-prescriber relationship). Rather, the telemedicine 
interview must be interactive and adaptive for the subsequent 
prescription to be considered valid.
The pharmacist should utilize prudent professional judgment 
when presented with a prescription generated from a telemedicine 
encounter. A complete copy of the Board of Medicine’s rules 
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vaccinating those who choose to be immunized; the impact on 
both individual and community immunity may be far-reaching.
4) Wrong Patient Errors: Not Opening the Bag at the Point 
of Sale
Community pharmacies are vulnerable to dispensing cor-
rectly filled prescriptions to the wrong patient at the point of 
sale, a risk that is well substantiated in the literature. This error 
is not influenced by the attributes of a specific medication; thus, 
dispensing any prescription medication to the wrong patient 
at the point of sale carries a similar level of risk. Based on an 
ISMP study, the error happens frequently at an estimated rate 
of 1.22 per 1,000 prescriptions. Among approximately 56,000 
community pharmacies in the United States, this error rate sug-
gests that 332,755 prescriptions will be dispensed to the wrong 
patient each month, or about six every month per pharmacy. One 
of the most effective ways to prevent this error is to open the 
bag of filled prescriptions at the point of sale to verify that the 
medications are for the correct patient. According to the ISMP 
study, this simple step reduces the risk of error by 56%, yet few 
pharmacies follow this practice.
5) Disrespectful Behavior: A History of Tolerance in Health 
Care
Bullying, incivility, and other forms of disrespectful behavior 
are still rampant in health care and allowed to exist. Health care 
providers tolerate the behavior, remain silent, or make excuses in 
an attempt to minimize the profound devastation that disrespect-
ful behavior causes. An ISMP survey conducted in 2003 clearly 
demonstrated the scope of disrespectful behavior among many 
levels of interdisciplinary staff, and an ISMP survey conducted a 
decade later demonstrates little progress. Disrespect diminishes 
a person’s ability to think clearly, make sound judgments, speak 
up regarding questions, or avoid at-risk behaviors. Disrespectful 
behaviors also underlie a resistance to collaborate with others, 
follow procedures that promote safe practices, or implement 
new safety practices. While a culture of disrespect is harmful 
on many levels, its effect on patient safety makes it a matter of 
national urgency.
FDA Advises Caution Against Codeine for 
Treating Colds in Young Patients
FDA is evaluating the safety of using medicines containing 
codeine to treat patients under 18 years old for coughs and 
colds because of the possibility of severe side effects. Codeine, 
an opioid, may cause slowed or difficult breathing in children, 
especially for those who already suffer from breathing problems, 
the agency notes. FDA recommends that health care providers use 
caution when prescribing or recommending codeine for patients 
under 18 years old, and that parents and caregivers be alert for 
signs of shallow or noisy breathing, confusion, or unusual sleepi-
ness. FDA is also considering a European Medicines Agency 
recommendation made in April to not give children under 12 
codeine for coughs and colds, and to not use codeine for patients 
12 to 18 years old who have asthma or other chronic breathing 
problems. More information is provided in an FDA safety alert 
available at www.fda.govSafety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm453379.htm.
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FDA Issues Warning About Name Confusion 
for Brintellix and Brilinta 
Due to similar brand names, there have been incidents where 
the antidepressant Brintellix® (vortioxetine) and the anti-blood 
clotting medication Brilinta® (ticagrelor) have been confused, re-
sulting in prescribing and dispensing errors, warns Food and Drug 
Administration (FDA). The agency notes that no reports indicate 
that a patient has ingested the wrong medication; however, reports 
of prescribing and dispensing errors continue. FDA recommends 
that health care providers include the generic name of the medi-
cation in addition to the brand name, as well as the indication 
for use when prescribing these medications. Patients are advised 
to check their prescriptions to ensure that the correct medica-
tion was dispensed. More information is available in an FDA 
safety alert at www.fda.gov/Safety/MedWatch/SafetyInformation/ 
SafetyAlertsforHumanMedicalProducts/ucm456569.htm.
Seven Persistent Safety Gaffes in 
Community/Ambulatory Settings That Need 
to Be Resolved!
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). 
ISMP is an independent nonprofit agency 
and federally certified patient safety organization that analyzes 
medication errors, near misses, and potentially hazardous 
conditions as reported by pharmacists and other practitioners. 
ISMP then makes appropriate contacts with companies and 
regulators, gathers expert opinion about prevention measures, 
and publishes its recommendations. To read about the risk 
reduction strategies that you can put into practice today, 
subscribe to ISMP Medication Safety Alert!® Community/
Ambulatory Care Edition by visiting www.ismp.org. ISMP 
provides legal protection and confidentiality for submitted 
patient safety data and error reports. Help others by reporting 
actual and potential medication errors to the ISMP National 
Medication Errors Reporting Program Report online at www 
.ismp.org. Email: ismpinfo@ismp.org.
This is part two of a three-part series on seven persistent safety 
gaffes of 2014.
3) Vaccine Errors: Repetitive Errors Reported in the Last 
Decade
How often do DTaP (diphtheria and tetanus toxoids, and acel-
lular pertussis) and Tdap (tetanus toxoid, reduced diphtheria tox-
oid, and acellular pertussis) vaccine mix-ups need to occur before 
regulatory action is taken to prevent confusion? Whatever the 
number, we can say that health care providers have probably met 
that threshold! Yet, vaccine errors like this continue to occur at an 
alarming rate (based on those reported to ISMP alone). Vaccine 
mix-ups occur often because of age-dependent formulations of 
the same vaccine, similar vaccine abbreviations, similar vaccine 
containers and labels, and storage near each other. Confusion 
between the diluent and vaccine has led to administration of the 
diluent alone or use of the wrong diluent. With an unfortunate 
rise in parents choosing not to vaccinate their children or them-
selves, health care providers cannot continue to make errors when 
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Daytrana Patch May Cause Permanent Skin 
Color Changes, FDA Warns
In June 2015, FDA warned health care providers and con-
sumers that Daytrana®, a methylphenidate transdermal system 
prescribed for treating attention deficit hyperactivity disorder, 
may cause permanent loss of skin color in the affected area. FDA 
has added a new warning to the drug label to describe this skin 
condition, known as chemical leukoderma. Chemical leukoderma 
is a skin condition that causes the skin to lose color as a result of 
repeated exposure to specific chemical compounds, according 
to an FDA safety alert. The condition is not physically harmful, 
but it is disfiguring.
FDA advises patients and caregivers to watch for new areas of 
lighter skin, especially under the drug patch, and to immediately 
report any changes to their health care providers. Patients should 
not stop using the Daytrana patch without consulting a health 
care provider. FDA also recommends that providers for patients 
who experience these skin color changes consider alternative 
treatments. More details are included in the FDA safety alert 
available at www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm452595.htm.
FDA Expands NSAID Warning Labels 
Regarding Risks of Heart Attack, Stroke
The labels of certain non-steroidal anti-inflammatory drugs 
(NSAIDs) will soon contain more detailed information about 
the risk that the drugs may contribute to heart attack and stroke, 
reports FDA. Such warnings have been on prescription and 
over-the-counter NSAIDs since 2005, but the new requirements 
take into account new data showing that the risk of heart attack 
and stroke occurs even during the first few weeks of taking an 
NSAID. People who have cardiovascular and other heart prob-
lems are at even greater risk of adverse effects. An FDA alert 
available at www.fda.gov/ForConsumers/ConsumerUpdates/
ucm453610.htm provides more details.
Baxter International, Inc, Recalls Three Lots 
of IV Solutions Due to Particulate Matter
In July 2015, Baxter International, Inc, voluntarily recalled 
two lots of intravenous (IV) solutions distributed to hospitals and 
other health offices because of the presence of particulate matter 
identified as an insect. The problem was identified before patient 
administration and no adverse health effects have been reported. 
The recall affects 0.9% sodium chloride injection, USP 50 mL 
and 100 mL, lot numbers P319921 and P327635, which were 
distributed to US customers between October 7, 2014, and July 
14, 2015. Additional information is available in an FDA press 
release at www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm455421.htm.
Baxter also voluntarily recalled one lot of IV solution to the 
hospital/user level because of the potential for leaking contain-
ers, particulate matter, and missing port protectors. This recall 
affects 0.9% sodium chloride injection, USP (AUTO-C) with lot 
number C964601 (National Drug Code 0338-0049-03; expira-
tion date: April 30, 2016). This recalled lot was distributed to 
customers and distributors nationwide between January 22, 2015, 
and February 12, 2015. Leaking containers, particulate matter, 
and missing port protectors could result in contamination of the 
solution and, if not detected, could lead to a bloodstream infec-
tion or other serious adverse health consequences, explains FDA. 
The agency notes further that “injecting a product containing 
particulate matter, in the absence of in-line filtration, may result 
in blockage of blood vessels, which can result in stroke, heart 
attack or damage to other organs such as the kidney or liver. 
There is also the possibility of allergic reactions, local irritation 
and inflammation in tissues and organs.” More information 
about this recall is available in an FDA safety alert at www.fda 
.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuman 
MedicalProducts/ucm456793.htm.
FDA Warns Against Unapproved 
Prescription Ear Drops
FDA has ordered the manufacturers of certain prescription 
ear drops to stop making and distributing the products because 
they are not FDA-approved. The product labels do not disclose 
that they lack FDA approval, and health care providers may 
not be aware of the unapproved status, notes FDA. The agency 
took action against unapproved prescription otic drug products 
containing these ingredients:
 ♦ benzocaine;
 ♦ benzocaine and antipyrine;
 ♦ benzocaine, antipyrine, and zinc acetate;
 ♦ benzocaine, chloroxylenol, and hydrocortisone;
 ♦ chloroxylenol and pramoxine; and
 ♦ chloroxylenol, pramoxine, and hydrocortisone.
These drugs are frequently given to relieve ear swelling and 
pain in young children, and FDA took this action to protect pa-
tients from the risks of taking unapproved drugs with no proven 
safety or effectiveness information. Further, such drugs may be 
contaminated or manufactured incorrectly, notes the agency. 
More information is provided in an FDA news release available 
at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm453348.htm.
Acino Products in New Jersey Ordered to 
Stop Selling Rectacort-HC and GRx HiCort 25
Under the direction of FDA, a federal judge for the District of 
New Jersey has ordered Acino Products, LLC, of Hamilton, NJ, 
to stop selling and destroy certain unapproved and misbranded 
prescription drugs in its possession.
According to FDA, Acino has marketed unapproved hydro-
cortisone acetate 25 mg suppositories, under the brand names 
Rectacort-HC and GRx HiCort 25, for treatment of medical 
conditions including inflamed hemorrhoids, chronic ulcerative 
colitis, and other inflammatory conditions. The drugs have not 
been FDA-approved and also fail to carry adequate directions 
for use on their labels. Acino continued to market and sell the 
products despite several warnings from FDA investigators. The 
FDA news release is available at www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm453466.htm.
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pertaining to telemedicine may be found at https://www.legis.iowa 
.gov/docs/ACO/agency/10-14-2015.653.pdf.
Technician and Support Person Registration 
Responsibilities
By Sue Mears, MBA, RPh, Board Compliance Officer
In the past few months, the Board has encountered a number of 
instances where a technician or pharmacy support person has failed 
to submit a timely registration or renewal application. Technicians 
and support persons must be registered with the Board within 30 
days of beginning employment in the pharmacy. Renewals must be 
submitted prior to the expiration date of the registration. A technician 
who is not nationally certified must register as a technician trainee 
for one year. Within that training year, the technician should be 
working toward attaining national certification. When the technician 
does successfully attain national certification, he or she may im-
mediately submit a registration application for a certified technician 
registration, or he or she may submit this application at the end of the 
technician trainee registration period. If, at the end of the technician 
trainee’s registration period, the trainee has not attained national cer-
tification, this employee can no longer conduct himself or herself as 
a pharmacy technician. If the employee continues employment in the 
pharmacy, he or she must register as a pharmacy support person and 
be assigned only those tasks that are allowed by Board rules. While 
it is the responsibility of each individual pharmacy staff member to 
maintain a current license or registration with the Board, it is the 
responsibility of the pharmacist-in-charge (PIC) to be aware of the 
current registration status of each of the pharmacy’s staff members. 
The PIC and owner are responsible for staffing the pharmacy with 
staff who are properly licensed or registered, and when an employee 
has not timely obtained a license or registration, that employee is not 
licensed or registered to be working in the pharmacy. If the PIC and 
owner allow an unlicensed or unregistered employee to work in the 
pharmacy, they may be at risk of disciplinary action by the Board.
Board Encourages Pharmacies to Purchase 
Drugs From Reputable Sources
Alpine Wellness, Inc (https://pharmacy.iowa.gov/document/
alpine-wellness-inc), a drug wholesaler located in Urbandale, IA, 
was issued an emergency adjudicative order and notice of hearing 
and statement of charges for engaging in unethical conduct harm-
ful to the public by failing to maintain records of all transactions 
regarding the receipt of prescription drugs and subverting a Board 
investigation. The emergency adjudicative order indefinitely 
suspends its Iowa wholesale drug license. The Board received a 
complaint alleging that Alpine was providing false information on 
transaction records. An inspection was performed on October 21, 
2015, by Board compliance officers. During the inspection, Board 
compliance officers found approximately six cardboard boxes 
containing what appeared to be brand-name, high-dollar prescrip-
tion drugs. Alpine was unable to produce any records demonstrating 
where it was shipping the prescription drugs. Alpine was instructed 
by Board compliance officers to keep the prescription drugs at 
its location until further notice. When Board compliance officers 
executed an administrative search warrant at its location on Octo-
ber 22, 2015, all of the cardboard boxes containing the drugs had 
been removed from the facility. The Board determined that the facts 
set forth established that Alpine’s continued operation as a drug 
wholesaler poses an immediate danger to the public health, safety, or 
welfare because the safety and authenticity of the prescription drugs 
cannot be verified. A hearing was scheduled for December 1, 2015.
The Board encourages pharmacists and pharmacies to verify 
Drug Supply Chain Security Act transaction records received from 
wholesalers, especially if the purchases are made from unaccredited 
facilities. If fictitious transaction records are discovered, the drugs 
must be quarantined and the incident reported to the Board as soon as 
it is reasonably possible. Wholesalers that hold Verified-Accredited 
Wholesale Distributors® accreditation through the National Associa-
tion of Boards of Pharmacy® (NABP®) have undergone a criteria 
compliance review, including a rigorous review of their operating 
policies and procedures, licensure verification, survey of the facil-
ity and operations, background checks, and screening through the 
NABP Clearinghouse. These wholesalers are reviewed annually 
and undergo a site survey every three years. Please visit www.nabp 
.net/programs for additional information regarding accreditation 
offerings.
Follow the Board on Facebook and Twitter
Continued from page 1
Facebook “Iowa Board of Pharmacy”
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
https://twitter.com/IABoardPharmacy
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